Ignite Creation Date:
2025-12-25 @ 1:32 AM
Ignite Modification Date:
2026-05-29 @ 11:10 AM
Study NCT ID:
NCT00754494
Status:
COMPLETED
Last Update Posted:
2015-01-06
First Post:
2008-09-17
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Adenomatous Polyp | View |
| None | Recurrent Colon Cancer | View |
| None | Recurrent Rectal Cancer | View |
| None | Stage I Colon Cancer | View |
| None | Stage I Rectal Cancer | View |
| None | Stage IIA Colon Cancer | View |
| None | Stage IIA Rectal Cancer | View |
| None | Stage IIB Colon Cancer | View |
| None | Stage IIB Rectal Cancer | View |
| None | Stage IIC Colon Cancer | View |
| None | Stage IIC Rectal Cancer | View |
| None | Stage IIIA Colon Cancer | View |
| None | Stage IIIA Rectal Cancer | View |
| None | Stage IIIB Colon Cancer | View |
| None | Stage IIIB Rectal Cancer | View |
| None | Stage IIIC Colon Cancer | View |
| None | Stage IIIC Rectal Cancer | View |
Keywords: